The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

277 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.EBI
Nanjing University
Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.EBI
Shandong University
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI
Universit£
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI
Florida Atlantic University
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI
Takeda Pharmaceutical
New matrix metalloproteinase inhibitors based on¿-fluorinateda-aminocarboxylic anda-aminohydroxamic acids.EBI
Westf£Lische Wilhelms-Universit£T M£Nster
A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.EBI
University Medical Center Groningen
Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.EBI
Eli Lilly
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI
Universidad Ceu San Pablo
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.EBI
Takeda Pharmaceutical
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.EBI
Universit£
Design, synthesis and preliminary evaluation ofa-sulfonyl¿-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.EBI
Shandong University
O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.EBI
University Of Notre Dame
A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.EBI
Asahi Kasei Pharma
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.EBI
Universit£
Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.EBI
Nanjing University Of Chinese Medicine
Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).EBI
Second Military Medical University
Sulphonamides: Deserving class as MMP inhibitors?EBI
Indian Institute Of Technology (Bhu)
Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI
Universit£
MMP inhibition by barbiturate homodimers.EBI
Trinity College
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI
Pomona College
Selective non zinc binding inhibitors of MMP13.EBI
Astrazeneca
Design and synthesis of procollagen C-proteinase inhibitors.EBI
Fibrogen
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.EBI
TBA
Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment.EBI
The Hebrew University Of Jerusalem
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI
Wroclaw University Of Technology
A one-pot synthesis and biological activity of ageladine A and analogues.EBI
Macquarie University
Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.EBI
Universit£
Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.EBI
Tianjin Medical University
A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.EBI
University Hospital M£Nster
Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.EBI
Trinity College
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI
TBA
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.EBI
East China University Of Science And Technology
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI
Alantos Pharmaceuticals
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.EBI
Shandong University
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University Of Florida
Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI
Incyte
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).EBI
Shandong University
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).EBI
Shandong University
Current perspective of TACE inhibitors: a review.EBI
The M. S. University Of Baroda
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.EBI
Johnson & Johnson Pharmaceutical Research And Development
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).EBI
Johnson & Johnson Pharmaceutical Research And Development
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.EBI
Johnson & Johnson Pharmaceutical Research And Development
Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI
The Hebrew University Of Jerusalem
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Research And Development
Synthesis and evaluation of novel heterocyclic MMP inhibitors.EBI
North Dakota State University
Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.EBI
University Hospital Of The Westf£Lische Wilhelms-Universit£T M£Nster
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI
Instituto Superior T£Cnico
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.EBI
Universit£
C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.EBI
University Hospital Of The Westf£Lische Wilhelms-Universit£T
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI
Universit£
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.EBI
Sejong University
Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.EBI
The Hebrew University Of Jerusalem
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.EBI
Institut De Recherches Servier
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI
Wyeth Research
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI
Dupont Pharmaceuticals
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI
TBA
Protease inhibitors: current status and future prospects.EBI
University Of Queensland
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI
Parke-Davis Pharmaceutical Research
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI
Procter And Gamble Pharmaceuticals
Inhibition of collagenase by aranciamycin and aranciamycin derivatives.EBI
Technical University Of Denmark
New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.EBI
Universit£
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI
Pfizer
Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.EBI
Pfizer
Heterocycle-based MMP inhibitors with P2' substituents.EBI
Procter And Gamble Pharmaceuticals
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.EBI
Pfizer
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.EBI
Celltech-Chiroscience
Synthesis and activity of selective MMP inhibitors with an aryl backbone.EBI
Pharmacia
Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.EBI
University Of Cambridge
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.EBI
Universit£
In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI
Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI
Pfizer
A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.EBI
University Hospital M£Nster
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI
Astrazeneca
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI
Boehringer Ingelheim Pharmaceuticals
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI
Instituto Superior T£Cnico
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).EBI
Pfizer
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI
Microbiotix
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.EBI
Universit£
Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.EBI
Novartis Institutes For Biomedical Research
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.EBI
Johnson & Johnson Pharmaceutical Research & Development
Selective water-soluble gelatinase inhibitor prodrugs.EBI
University Of Notre Dame
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.EBI
Shandong University
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.EBI
Shandong University
N-substituted homopiperazine barbiturates as gelatinase inhibitors.EBI
Trinity College
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI
Pfizer
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI
Universit£
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI
Astrazeneca
Structure and activity relationships of tartrate-based TACE inhibitors.EBI
Merck Research Laboratories
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI
Pfizer
MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI
Pfizer
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI
Merck Research Laboratories
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI
Astrazeneca
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.EBI
University Of California
Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI
TBA
2-Azetidinone--a new profile of various pharmacological activities.EBI
Barkatullah University
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI
Merck Research Laboratories
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.EBI
Shandong University
MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI
Pfizer
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI
Pfizer
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI
Universit£
Discovery and SAR of hydantoin TACE inhibitors.EBI
Merck Research Laboratories
Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.EBI
Wonkwang University Sanbon Medical Center
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI
Schering-Plough Research Institute
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.EBI
Shandong University
Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).EBI
Shandong University
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
Synthesis and anticancer activities of ageladine A and structural analogs.EBI
Beckman Research Institute At City Of Hope
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.EBI
Shandong University
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI
Gsk Medicines Research Centre
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI
Universit£
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.EBI
Shandong University
3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.EBI
Wyeth Research
Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.EBI
University Of Shizuoka And Global Coe Program
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI
Wyeth Research
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI
Universit£
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI
Schering-Plough Research Institute
 
Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinasesEBI
TBA
 
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI
TBA
 
Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimicsEBI
TBA
 
Orally active inhibitors of stromelysin-1 (MMP-3)EBI
TBA
 
Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptidesEBI
TBA
 
Phosphinic acid inhibitors of matrix metalloproteinasesEBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'EBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalaninesEBI
TBA
 
Novel indolactam-based inhibitors of matrix metalloproteinasesEBI
TBA
 
Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivativesEBI
TBA
 
Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivativesEBI
TBA
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI
Incyte
Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI
Wyeth Research
Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.EBI
Wyeth Research
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.EBI
University Of California
Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI
Instituto Superior TéCnico
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).EBI
Shandong University
Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI
Pfizer
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI
University Of Athens
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI
Université
Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI
Shandong University
Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.EBI
Shandong University
Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.EBI
Shandong University
Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI
Shandong University
Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.EBI
Shandong University
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI
Università
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI
Pfizer
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.EBI
Johnson & Johnson Pharmaceutical Research And Development
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI
Incyte
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI
Incyte
A novel series of highly selective inhibitors of MMP-3.EBI
Pfizer
Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.EBI
Yonsei University
Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI
Pfizer
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.EBI
Università
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.EBI
Wyeth Research
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI
Université
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.EBI
Shandong University
Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2.EBI
Korea Research Institute Of Bioscience And Biotechnology
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.EBI
Clermont Auvergne University
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI
Incyte
Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI
Università
Identification of potent and selective TACE inhibitors via the S1 pocket.EBI
Wyeth Research
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI
Wyeth Research
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.EBI
Johnson & Johnson Pharmaceutical Research And Development
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI
Chinese Academy Of Sciences
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI
Aventis Pharma Deutschland
Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.EBI
Università
Synthesis and SAR of highly selective MMP-13 inhibitors.EBI
Wyeth Research
Identification of potent and selective MMP-13 inhibitors.EBI
Wyeth Research
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.EBI
Pfizer
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI
Pfizer
Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI
Università
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.EBI
Pfizer
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI
Pharmaceutical Research Institute
Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of novel oxazoline MMP inhibitors.EBI
North Dakota State University
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI
Pfizer
A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.EBI
University Of California San Francisco
Reverse hydroxamate-based selective TACE inhibitors.EBI
Kaken Pharmaceutical
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI
University Of Athens
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI
Chinese Academy Of Sciences
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.EBI
Umr/Cnrs 6013
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI
Pfizer
Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.EBI
National Cardiovascular Center Research Institute
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI
Indiana University School Of Medicine
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.EBI
Université
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI
Bristol-Myers Squibb
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI
Abbott Laboratories
Potent P1' biphenylmethyl substituted aggrecanase inhibitors.EBI
Bristol-Myers Squibb Pharma
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.EBI
Abbott Laboratories
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI
Dupont Pharmaceuticals
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.EBI
Dupont Pharmaceuticals
Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI
UniversitäT Bielefeld
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI
British Biotech Pharmaceuticals
Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.EBI
Université
N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.EBI
Université
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI
Procter And Gamble Pharmaceuticals
A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.EBI
The Royal Danish School Of Pharmacy
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI
Abbott Laboratories
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.EBI
Abbott Laboratories
Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.EBI
Pfizer
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI
Roche Research Center
Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.EBI
Procter And Gamble Pharmaceuticals
Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.EBI
University Of Florida
Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI
Pfizer
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI
Pfizer
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.EBI
Institut De Recherches Servier
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI
Procter And Gamble Pharmaceuticals
Solid-phase synthesis of an arylsulfone hydroxamate library.EBI
Rhone-Poulenc Rorer
Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.EBI
Pfizer
Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.EBI
Università
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI
University Of Florida
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.EBI
British Biotech Pharmaceuticals
Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.EBI
University Of Wisconsin-Madison
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI
Cea
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.EBI
Shionogi
Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.EBI
RhôNe-Poulenc Rorer
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.EBI
Pfizer
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI
Abbott Laboratories
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI
Abbott Laboratories
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.EBI
Abbott Laboratories
Macrocyclic amino carboxylates as selective MMP-8 inhibitors.EBI
Dupont Pharmaceuticals
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI
Kanebo
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI
Shionogi
Matrix metalloproteinase inhibitors: a structure-activity study.EBI
Glycomed
Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.EBI
Institut De Recherche Servier
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.EBI
Merck Research Laboratories
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.EBI
Merck Research Laboratories
Cyclic peptides with a phosphinic bond as potent inhibitors of a zinc bacterial collagenase.EBI
University Of Athens
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB
Suven Life Sciences
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.BDB
Torrey Pines Institute For Molecular Studies
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.BDB
Purdue University
YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.BDB
Yamanouchi Pharmaceutical
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.BDB
National Institute Of Neurological Disorders And Stroke
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.BDB
Abbott Laboratories
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.BDB
Syntex Discovery Research
Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.BDB
Novo Nordisk
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.BDB
Fujisawa Pharmaceutical
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.BDB
St. Jude Research Hospital
Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.BDB
Chemical Genomics Centre Of The Max Planck Society
A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.BDB
Virginia Commonwealth University
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.BDB
Max Planck Institute
Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold.BDB
Merck Serono
Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.BDB
Acadia Pharmaceuticals
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.BDB
Universita Del Piemonte Orientale
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.BDB
Pfizer
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity.BDB
University Of St. Andrews